Amendments to the Claims

Please amend the claims as follows:

1.-4. (Cancelled)

5. (Currently amended) A compound of the formula:



Formula I

wherein,

R1 represents hydrogen, halo, or (C1-C4)alkyl; and

R2 represents:

(a) aryl;

(b) aryl optionally substituted one to three times with a substituent independently selected from the group consisting of:

(i) halo,
(ii) amino,
(iii) nitro,
(iv) hydroxy,
(v) cyano,
(vi) $(C_1\text{-}C_4)$alkyl,
(vii) $(C_1\text{-}C_4)$alkoxy,
(viii) hydroxy$(C_1\text{-}C_4)$alkyl,
(ix) amino$(C_1\text{-}C_4)$alkyl
(x) hydroxy$(C_1\text{-}C_4)$alkoxy,
(xi) halo$(C_1\text{-}C_4)$alkoxy,
(xii) $(C_1\text{-}C_4)$alkoxy$(C_1\text{-}C_4)$alkoxy,
(xiii) trifluoromethyl,
(xiv) difluoromethyl,
(xv) trifluromethoxy,
(xvi) difluoromethoxy,

(xvii) (C_3-C_7)cylcoalkyl,

(xviii) COR^3,

(xix) (C_1-C_4)alkyl-COR4,

(xx) amino(C_1-C_4)alkyl- COR4,

(xxi) hydroxy(C_1-C_4)alkyl- COR4

(xxii) (C_1-C_4)alkoxy-COR5,

(xxiii) –$C(NH_2)$=N-OH

(xxiv) $NHSO_2R^6$,

(xxv) SO_2R^7,

(xxvi) $NHCOR^8$,

(xxvii) SOR^9,

(xxviii)SR^{10},

(xxix) $CONHR^{11}$,

(xxx) O–(CH_2)q–$NR^{12}R^{13}$, wherein q represents 1-4,

(xxxi) tetrazole,

(xxxii) methyltetrazole, and

(xxxiii) CONCH-$NR^{15}R^{16}$

~~(c) heterocycle;~~

~~(d) heterocycle optionally substituted one to three times with a substituent independently selected from the group consisting of:~~

~~(i) halo,~~

~~(ii) amino,~~

~~(iii) (C_1-C_4)alkyl,~~

~~(iv) (C_1-C_4)alkoxy,~~

~~(v) halophenyl(C_1-C_4)alkyl,~~

~~(vi) (C_1-C_4)alkyl (C_1-C_4)alkoxycarbonyl,~~

~~(vii) CHO,~~

~~(viii) COR^3, and~~

~~(ix) SO_2R^7;~~

~~(e) benzofused heterocycle;~~

~~(f) benzofused heterocycle optionally substituted one or two times with a substituent independently selected from the group consisting of:~~

~~(i) halo,~~

~~(ii) amino,~~

~~(iii) (C_1-C_4)alkyl,~~

~~(iv) (C_1-C_4)alkoxy, and~~

~~(v) (C_1-C_4)alkylcarbonyl, or~~

~~(g) (C_3-C_7)cylcoalkyl;~~

(c) thiophen-2-yl, thiophen-3-yl, pyridin-4-yl, pyridin-3-yl, furan-3-yl, furan-2-yl, thiazol-2-yl, pyrazin-2-yl, pyridin-2-yl, 1H-pyrrol-2-yl, 1H-pyrrol-3-yl, pyrimidin-2-yl, pyrimidin-5-yl, imidazol-1-yl, [1,2,4]triazol-1-yl, pyrazol-1-yl, [1,2,3]triazol-1-yl, piperidin-1-yl, 1,1-Dioxo-1λ6-thiomorph-olin-4-yl, piperazin-1-yl, 4-methylthiophen-2-yl, 6-carboxypyridin-2-yl, 5-fluoropyridin-2-yl, 6-methoxypyridazin-3-yl, 2-aminopyrimidin-5-yl, 5-aminosulfonyl thiophen-2-yl, or 4-tert-butoxycarbonyl piperazin-1-yl;

(d) benzofused heterocycle;

(e) benzofused heterocycle optionally substituted one or two times with a substituent independently selected from the group consisting of:

(i) halo,

(ii) amino,

(iii) $(C_1\text{-}C_4)$alkyl,

(iv) $(C_1\text{-}C_4)$alkoxy, and

(v) $(C_1\text{-}C_4)$alkylcarbonyl, or

(f) $(C_3\text{-}C_7)$cycloalkyl;

R^3 represents independently at each occurrence amino, hydroxy, $(C_1\text{-}C_4)$alkyl, $(C_1\text{-}C_4)$alkoxy, NH-$(C_1\text{-}C_4)$alkylamine, N,N-$(C_1\text{-}C_4)$dialkylamine, or a heterocycle selected from the group consisting of:



(a) , (b) , (c)



(d) , or (e)



(a) , (b) , (c)



(d) , or (e)

R^4 and R^5 represent independently at each occurrence amino, hydroxy, $(C_1$-$C_4)$alkyl, or $(C_1$-$C_4)$alkoxy;

R^6 and R^7 represent independently at each occurrence amino or (C1-C4)alkyl;

R^8 represents independently at each occurrence amino, $(C_1$-$C_4)$alkyl, or $(C_1$-$C_4)$alkoxy;

R^9 and R^{10} represent independently at each occurrence (C1-C4)alkyl;

R^{11} represents independently at each occurrence (C1-C4)alkyl or a substituent selected from the group consisting of:

(a) $-(CH_2)_n-X-Y$

(b) $-CH(COR^{14})-(CH_2)_m-X'-Y'$

(c) 

(d) 

and (e) 

wherein,

n and m each independently represent 0-4;

X and X' represent independently at each occurrence –CO-, $-CH_2-$, -NH-, -S-, or $-SO_2-$; and

Y and Y' represent independently at each occurrence amino, hydroxy, (C_1-C_4)alkyl, (C_1-C_4)alkoxy, (C_1-C_4)alkoxycarbonyl, NH-(C_1-C_4)alkylamine, or N,N-(C_1-C_4)dialkylamine,

provided that where X or X' represents S, then Y or Y'' is not amino or hydroxy;

R^{12} and R^{13} represent independently at each occurrence hydrogen or (C_1-C_4)alkyl, or R^{12} and R^{13} together with the nitrogen atom to which they are attached form a piperidino, pyrrolidino, morpholino or a methylpiperazino group;

R^{14} represents independently at each occurrence hydroxy, amino, or (C_1-C_4)alkoxy; and

R^{15} and R^{16} each represent independently at each occurrence hydrogen or (C_1-C_4)alkyl,

or a pharmaceutically acceptable salt thereof.

6. (Previously presented) The compound according to Claim 5 wherein R1 represents hydrogen or (C_1-C_4)alkyl.

7. (Previously presented) The compound according to Claim 6 wherein R1 represents hydrogen or methyl.

8. (Previously presented) The compound according to Claim 5 wherein R2 represents

(a) phenyl;

(b) phenyl optionally substituted one to three times with a substituent independently selected from the group consisting of:

(i) halo,
(ii) amino,
(iii) nitro,
(iv) hydroxy,
(v) cyano,
(vi) $(C_1\text{-}C_4)$alkyl,
(vii) $(C_1\text{-}C_4)$alkoxy,
(viii) amino$(C_1\text{-}C_4)$alkyl
(ix) hydroxy$(C_1\text{-}C_4)$alkoxy,
(x) halo$(C_1\text{-}C_4)$alkoxy,
(xi) $(C_1\text{-}C_4)$alkoxy$(C_1\text{-}C_4)$alkoxy,
(xii) trifluoromethyl,
(xiii) $(C_3\text{-}C_7)$cylcoalkyl,
(xiv) COR^3,
(xv) $(C_1\text{-}C_4)$alkyl-COR4,
(xvi) $(C_1\text{-}C_4)$alkoxy-COR5,
(xvii) $NHSO_2R^6$,
(xviii) SO_2R^7,
(xix) $NHCOR^8$,
(xx) SOR^9,
(xxi) SR^{10},
(xxii) $CONHR^{11}$, and
(xxiii) $O\text{–}(CH_2)q\text{–}NR^{12}R^{13}$, wherein q represents 1-4,

(c) thiopheneyl, furanyl, imidazolyl, pyrazolyl, pyrrolyl, thiazolyl, triazolyl, pyridinyl, pyrimidyl, pyrazinyl, pyridiazinyl, piperidinyl, piperazinyl, pyrimidinyl, or dioxo-thiomorpholinyl,;

(d) thiopheneyl, furanyl, imidazolyl, pyrazolyl, pyrrolyl, thiazolyl, triazolyl, pyridinyl, pyrimidyl, pyrazinyl, pyridiazinyl, piperidinyl, piperazinyl, pyrimidinyl, or dioxo-thiomorpholinyl optionally substituted one to three times with a substituent independently selected from the group consisting of:

(i) fluoro, bromo, or chloro,
(ii) amino,
(iii) (C_1-C_4)alkyl,
(xxiv) (C_1-C_4)alkoxy,
(xxv) COR_3 , and
(xxvi) SO_2R^7,

(e) benzimidazole, benzofuran, benzothiophene, benzo[1,3]-dioxolyl, benzothiazole, 2,2-dioxy-2,3-dihydro-lH-2λ^6-benzo[c]thiophene, or indole;

(f) benzimidazole, benzofuran, benzothiophene, benzo[1,3]-dioxolyl, benzothiazole, 2,2-dioxy-2,3-dihydro-IH-2λ^6-benzo[c]thiophene, and indole optionally substituted one or two times with a substituent independently selected from the group consisting of:
(i) amino, and
(ii) (C_1-C_4)alkyl; or

(g) cyclohexyl.

9. (Previously presented) The compound according to Claim 8 wherein R2 represents

(a) phenyl;

(b) phenyl optionally substituted one to three times with a substituent independently selected from the group consisting of:
(i) fluoro, bromo, or chloro,
(ii) amino,
(iii) nitro,
(iv) hydroxy,
(v) cyano,
(vi) methyl, ethyl, propyl, butyl, i-butyl,
(vii) methoxy or ethoxy,
(viii) aminomethyl or aminoethyl,
(ix) hydroxy methoxy or hydroxy ethoxy,
(x) 2-fluoro ethoxy or 2-trifluoro ethoxy,
(xi) methoxy ethoxy,
(xii) trifluoromethyl,
(xiii) cyclohexyl,
(xiv) COR^3, wherein R3 represents amino, hydroxy, (C_1-C_4)alkyl, (C_1-C_4)alkoxy, N,N-(C_1-C_4)dialkylamine,
or a heterocycle selected from the group consisting of:



(a) , (b) , (c)



(d) , or (e)



(i) , (ii) , (iii)



(iv) , or (v)

(xv) (C_1-C_4)alkyl-COR4, wherein R4 represents hydroxy, amino, or (Cl-C4)alkoxy,

(xvi) (C_1-C_4)alkoxy-COR5, wherein R5 represents hydroxyl or amino,

(xvii) $NHSO_2R^6$, wherein R6 represents (Cl-C4)alkyl,

(xviii) SO_2R^7, wherein R7 represents amino or (C1-C4)alkyl,

(xix) $NHCOR^8$, wherein R8 represents methyl,

(xx) SOR^9, wherein R9 represents methyl,

(xxi) SR^{10}, wherein RI0 represents methyl or ethyl,

(xxii) $CONHR^{11}$, wherein R11 represents -(CH_2)n-X-Y, where n=0-2, X represents -S-, -CH_2-, -(CH_2)$_2$-, -NH-, -CO-, or -SO_2-, and Y represents amino, (Cl-C4)alkyl, (Cl-C4)alkoxycarbonyl, or NH-(Cl-C4)alkylamine; or wherein R11 represents CH(COR14)-(CH_2)m-X'-Y" where R14 represents hydroxy or (Cl-C4)alkoxy, m=0-4, X' represents -S-, -CH_2-, -NH-, or -CO-, and Y' represents represents amino, hydroxy, (Cl-C4)alkyl, or (Cl-C4)alkoxycarbonyl; or wherein R11 represents a group selected from the following:

(a) 

(b) 

and (c) 

(xxiii) O-(CH_2)q-$NR^{12}R^{13}$, wherein q represents 1-3, R12 and R13 independently represent hydrogen or methyl or R12 and R13 together with the nitrogen to which they are attached form a piperidino, pyrrolidino, morpholino or a methylpiperazino group;

(c) thiopheneyl, furanyl, imidazolyl, pyrazolyl, pyrrolyl, thiazolyl, triazolyl, pyridinyl, pyrimidyl, pyrazinyl, pyridiazinyl, piperidinyl, piperazinyl, pyrimidinyl, or dioxo-thiomorpholinyl,;

(d) thiopheneyl, furanyl, imidazolyl, pyrazolyl, pyrrolyl, thiazolyl, triazolyl, pyridinyl, pyrimidyl, pyrazinyl, pyridiazinyl, piperidinyl, piperazinyl, pyrimidinyl, or dioxo-thiomorpholinyl optionally substituted one to three times with a substituent independently selected from the group consisting of:

(i) fluoro, bromo, or chloro,

(ii) amino,

(iii) methyl,

(iv) methoxy,

(v) COR^3, wherein R3 represents hydroxy, (Cl-C4)alkoxy or pyridine,

(vi) SO_2R^7, wherein R7 represents amino

(e) benzimidazole, benzofuran, benzothiophene, benzo[1,3]-dioxolyl, benzothiazole, 2,2-dioxy-2,3-dihydro-lH-2λ^6-benzo[c]thiophene, or indole;

(f) benzimidazole, benzofuran, benzothiophene, benzo[1,3]-dioxolyl, benzothiazole, 2,2-dioxy-2,3-dihydro-lH-2λ^6-benzo[c]thiophene, and indole optionally substituted one or two times with a substituent independently selected from the group consisting of:

(i) amino, or

(ii) methyl; or

(g) cyclohexyl.

10. (Previously presented) The compound according to Claim 9 wherein R2 represents phenyl or phenyl optionally substituted one to three times with a substituent independently selected from the group consisting of:

(i) fluoro, bromo, or chloro,

(ii) amino,

(iii) nitro,

(iv) hydroxy,

(v) cyano,

(vi) methyl, ethyl, propyl, butyl, i-butyl,

(vii) methoxy or ethoxy,

(viii) aminomethyl or aminoethyl,

(ix) hydroxy methoxy or hydroxy ethoxy,

(x) 2-fluoro ethoxy or 2-trifluoro ethoxy,

(xi) methoxy ethoxy,

(xii) trifluoromethyl,

(xiii) cyclohexyl,

(xiv) COR^3, wherein R3 represents amino, hydroxy, (Cl-C4)alkyl, (Cl-C4)alkoxy, N,N-(C1 -C 4)dialkyiamine, or a heterocycle selected from the group consisting of:



(a) , (b) , (c)



(d) , or (e)



(i) , (ii) , (iii)

(iv) , or (v)

(xv) (C_1-C_4)alkyl-COR4, wherein R4 represents hydroxy, amino, or (Cl-C4)alkoxy,

(xvi) (C_1-C_4)alkoxy-COR5, wherein R5 represents hydroxyl or amino,

(xvii) $NHSO_2R^6$, wherein R6 represents (Cl-C4)alkyl,

(xviii) SO_2R^7, wherein R7 represents amino or (C1-C4)alkyl,

(xix) $NHCOR^8$, wherein R8 represents methyl,

(xx) SOR^9, wherein R9 represents methyl,

(xxi) SR^{10}, wherein RI0 represents methyl or ethyl,

(xxii) $CONHR^{11}$, wherein R11 represents -(CH_2)n-X-Y, where n=0-2, X represents -S-, -CH_2 -, -$(CH_2)_2$-, -NH-, -CO-, or -SO_2 -, and Y represents amino, (Cl-C4)alkyl, (Cl-C4)alkoxycarbonyl, or NH-(Cl-C4)alkylamine; or wherein R11 represents CH(COR14)-(CH_2)m-X'-Y" where R14 represents hydroxy or (Cl-C4)alkoxy, m=0-4, X' represents -S-, -CH_2 -, -NH-, or -CO-, and Y' represents represents amino, hydroxy, (Cl-C4)alkyl, or (Cl-C4)alkoxycarbonyl; or wherein R11 represents a group selected from the following:

(a) 

(b) 

and (c) 

(xxiii) O-(CH_2)q-$NR^{12}R^{13}$, wherein q represents 1-3, R12 and R13 independently represent hydrogen or methyl or R12 and R13 together with the nitrogen to which they are attached form a piperidino, pyrrolidino, morpholino or a methylpiperazino group.

11. (Previously presented) The compound according to Claim 9 wherein R2 represents thiopheneyl, furanyl, imidazolyl, pyrazolyl, pyrrolyl, thiazolyl, triazolyl, pyridinyl, pyrimidyl, pyrazinyl, pyridiazinyl, piperidinyl, piperazinyl, pyrimidinyl, dioxothiomorpholinyl; or thiophenyl, furanyl, imidazolyl, pyrazolyl, pyrrolyl, thiazolyl, triazolyl, pyridinyl, pyrimidyl, pyrazinyl, pyridiazinyl, piperidinyl, piperazinyl, pyrimidinyl, or dioxo-thiomorpholinyl optionally substituted one to three times with a substituent independently selected from the group consisting of:

(i) fluoro, bromo, or chloro,
(ii) amino,
(iii) methyl,
(iv) methoxy,
(v) COR^3, wherein R3 represents hydroxy or (Cl-C4)alkoxy,
(vi) SO_2R^7, wherein R7 represents amino.

12. (Previously presented) The compound according to Claim 9 wherein R2 represents benzimidazole, benzofuran, benzothiophene, benzo[1,3]-dioxolyl, benzothiazole, 2,2-dioxy-2,3-

dihydro- I H-2λ^6-benzo[c]thiophene, indole; or benzoimidazole, benzofuran, benzothiophene, benzo[1,3]-dioxolyl, benzothiazole, 2,2-dioxy-2,3-dihydro- I H-2λ^6-benzo[c]thiophene, or indole optionally substituted one or two times with a substituent independently selected from the group consisting of:

(i) amino, or

(ii) methyl.

13. (Previously presented) A pharmaceutical composition comprising as an active ingredient a compound according to Claim 5 in combination with a pharmaceutically acceptable carrier, diluent or excipient.

14. (Cancelled)